EP
VRDN icon

Essential Partners’s Viridian Therapeutics VRDN Stock Holding History

Essential Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$569 Buy
+31
New +$499 ﹤0.01% 2444

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Essential Partners's VRDN Position: Q2 2026 in Review

Essential Partners opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 31 shares worth $569. The stake represents ﹤0.01% of the portfolio and ranks #2444 among its holdings.

212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Essential Partners held 31 shares of Viridian Therapeutics worth $569 as of Q2 2026.
  • Viridian Therapeutics was a new Essential Partners position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2444 holding.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.